RESUMEN
Nicotine intake is linked to the maintenance and development of anxiety disorders and impairs adaptive discrimination of threat and safety in rodents and humans. Yet, it is unclear if nicotine exerts a causal pharmacological effect on the affective and neural mechanisms that underlie aversive learning. We conducted a pre-registered, pseudo-randomly and double-blinded pharmacological fMRI study to investigate the effect of acute nicotine on Fear Acquisition and Extinction in non-smokers (n = 88). Our results show that nicotine administration led to decreased discrimination between threat and safety in subjective fear. Nicotine furthermore decreased differential (threat vs. safety) activation in the hippocampus, which was functionally coupled with Nucleus Accumbens and amygdala, compared to placebo controls. Additionally, nicotine led to enhanced physiological arousal to learned threats and overactivation of the ventral tegmental area. This study provides mechanistic evidence that single doses of nicotine impair neural substrates of adaptive aversive learning in line with the risk for the development of pathological anxiety.
Asunto(s)
Amígdala del Cerebelo , Miedo , Hipocampo , Imagen por Resonancia Magnética , Nicotina , Núcleo Accumbens , Humanos , Nicotina/farmacología , Nicotina/efectos adversos , Nicotina/administración & dosificación , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/diagnóstico por imagen , Masculino , Hipocampo/efectos de los fármacos , Miedo/efectos de los fármacos , Adulto , Amígdala del Cerebelo/efectos de los fármacos , Amígdala del Cerebelo/diagnóstico por imagen , Femenino , Adulto Joven , Método Doble Ciego , Discriminación en Psicología/efectos de los fármacos , Agonistas Nicotínicos/farmacología , Agonistas Nicotínicos/efectos adversos , Agonistas Nicotínicos/administración & dosificación , Extinción Psicológica/efectos de los fármacosRESUMEN
Existing maze apparatuses used in rodents often exclusively assess spatial discriminability as a means to evaluate learning impairments. Spatial learning in such paradigms is reportedly spared by moderate prenatal alcohol exposure in rats, suggesting that spatial reinforcement alone is insufficient to delineate executive dysfunction, which consistently manifests in humans prenatally-exposed to alcohol. To address this, we designed a single-session continuous performance task in the T-maze apparatus that requires rats to discriminate within and between simultaneously-presented spatial (left or right) and tactile (sandpaper or smooth) stimuli for food reinforcement across four sequential discrimination stages: simple discrimination, intradimensional reversal 1, extradimensional shift, and intradimensional reversal 2. This design incorporates elements of working memory, attention, and goal-seeking behavior which collectively contribute to the executive function construct. Here, we found that rats prenatally-exposed to alcohol performed worse in both the tactile intradimensional reversal and extradimensional shift; alternatively, rats prenatally-exposed to alcohol acquired the extradimensional shift faster when shifting from the tactile to spatial dimension. In line with previous work, moderate prenatal alcohol exposure spared specifically spatial discrimination in this paradigm. However, when tactile stimuli were mapped into the spatial dimension, rats prenatally-exposed to alcohol required more trials to discriminate between the dimensions. We demonstrate that tactile stimuli can be operantly employed in a continuous performance T-maze task to detect discriminatory learning impairments in rats exposed to moderate prenatal alcohol. The current paradigm may be useful for assessing features of executive dysfunction in rodent models of fetal alcohol spectrum disorders.
Asunto(s)
Etanol , Aprendizaje por Laberinto , Efectos Tardíos de la Exposición Prenatal , Animales , Embarazo , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Femenino , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Etanol/farmacología , Etanol/administración & dosificación , Etanol/efectos adversos , Masculino , Ratas , Ratas Long-Evans , Percepción Espacial/efectos de los fármacos , Percepción Espacial/fisiología , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Percepción del Tacto/fisiología , Percepción del Tacto/efectos de los fármacos , Memoria a Corto Plazo/efectos de los fármacos , Memoria a Corto Plazo/fisiología , Trastornos del Espectro Alcohólico Fetal/fisiopatología , Tacto/fisiología , Tacto/efectos de los fármacosRESUMEN
RATIONALE: No previous studies examined the discriminative stimulus effects of intravenous (IV) nicotine in humans. OBJECTIVES: To evaluate a pulsed IV nicotine infusion procedure designed to mimic inhaled nicotine delivery and to identify a range of nicotine doses that may capture the threshold doses for the subjective and discriminative stimulus effects of nicotine. By determining these thresholds, we can gain valuable insights into the addictive threshold of nicotine. METHODS: Eleven participants had 2 Test Sessions following overnight abstinence from smoking. Test Session 1 examined participants' ability to discriminate 0.1 mg nicotine/pulse nicotine from saline. Test Session 2 examined if participants can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline. These nicotine doses were delivered as a cluster of 4 pulsed-nicotine infusions of 2-second duration with a 28-second interval between each pulse. RESULTS: The lowest doses of nicotine that produced greater responses than saline for discrimination, subjective effects, and heart rate ranged from 0.05 to 0.1 mg nicotine/pulse. CONCLUSIONS: These findings support the validity of our pulsed-infusion procedure as a model for nicotine delivery by smoking and its utility in examining factors that may impact the addictive threshold of nicotine.
Asunto(s)
Relación Dosis-Respuesta a Droga , Frecuencia Cardíaca , Nicotina , Humanos , Nicotina/administración & dosificación , Masculino , Adulto , Femenino , Infusiones Intravenosas , Adulto Joven , Frecuencia Cardíaca/efectos de los fármacos , Fumar , Agonistas Nicotínicos/administración & dosificación , Agonistas Nicotínicos/farmacología , Discriminación en Psicología/efectos de los fármacosRESUMEN
Recently, the abuse of synthetic cathinones is increasing among young people. α-Pyrrolidinobutiothiophenone (α-PBT), a synthetic cathinone, is a designer drug that is freely traded online with no legal restrictions. Moreover, there is currently no scientific basis for legal regulation. Here, we examined the addictive properties of α-PBT using a drug discrimination (DD) task. We also investigated the role of α-PBT in brain stimulation reward (BSR) using an intracranial self-stimulation (ICSS) paradigm in rats. Initially, the rats were trained to discriminate between cocaine and saline. After the discrimination training criteria were met, we determined the dose-effect curves of cocaine and conducted generalization tests with α-PBT and α-pyrrolidinopentiothiophenone (α-PVT) using a cumulative dosing protocol. In a separate set of studies, we examined the dopaminergic mechanisms underlying the function of α-PBT as an interoceptive stimulus (17.8 mg/kg) by intraperitoneally injecting either the dopamine (DA) D1 antagonist SCH23390 (0.06 and 0.12 mg/kg) or the D2 antagonist eticlopride (0.05 and 0.1 mg/kg) 15 min before DD testing. Brain reward function was measured using an ICSS procedure to examine the effects of α-PBT on ICSS threshold under the frequency-rate procedure. Our results showed that α-PBT functioned as a discriminative cue similar to cocaine in rats. More importantly, SCH23390 abolished the effects of α-PBT as an interoceptive stimulus in a dose-dependent manner in rats trained to press a lever to receive cocaine. Similarly, eticlopride dose-dependently attenuated the effect of α-PBT used as a discriminative cue. Additionally, cumulative α-PBT administration dose-dependently lowered ICSS thresholds compared with those in saline-treated rats. Furthermore, α-PBT-induced potentiation of BSR was abolished by pretreatment with both SCH23390 and eticlopride. Taken together, our results suggest that α-PBT can function as a cocaine-like discriminative cue via the activation of D1 and D2 receptors. α-PBT also appears to influence BSR by reducing the brain reward threshold via changes in D1 and D2 receptors. The present study suggests that α-PBT could have addictive properties through DA D1 and D2 receptors and thus poses a threat to humans.
Asunto(s)
Cocaína , Autoestimulación , Animales , Masculino , Autoestimulación/efectos de los fármacos , Ratas , Cocaína/farmacología , Ratas Sprague-Dawley , Pirrolidinas/farmacología , Recompensa , Relación Dosis-Respuesta a Droga , Tiofenos/farmacología , Benzazepinas/farmacología , Drogas de Diseño/farmacología , Discriminación en Psicología/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismoRESUMEN
Nicotine functions effectively as an interoceptive operant discriminative stimulus (SD) that sets the occasion for voluntarily emitted behavior to be reinforced by biologically relevant outcomes (e.g., food). This has been demonstrated primarily with male rats. Far less is known about nicotine's operant SD functions in female rats. There are no reports of sex differences in extinction and recovery of the SD functions of nicotine, which may elucidate smoking cessation and relapse. In view of this, eight male and eight female rats were trained to nose poke differentially among quasirandomly intermixed sessions of food reinforcement variable interval (VI-30 s) and nonreinforcement in a go/no-go across session one-manipulanda operant drug discrimination procedure. For half the rats, presession administration of nicotine (0.30 mg/kg, subcutaneous) occasioned reinforcement sessions of nose pokes (i.e., SD); for the remaining rats, it occasioned nonreinforcement (SΔ). Saline sessions occasioned the opposite contingencies. Training was conducted first under feeding restriction and then under free feeding, which was then followed by extinction sessions that were also conducted with free feeding. During discrimination training, response rates for females did not differ from males when conducted under restricted feeding but did so during training and later extinction conducted under free feeding. Females also exhibited greater reinstatement of responding under the nicotine SD but not the SΔ. These data provide additional evidence for sex differences in rats with the discriminative stimulus functions of nicotine under low, but not high, food-drive states-and may have implications for sex/gender differences in smoking cessation and relapse. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Asunto(s)
Condicionamiento Operante , Extinción Psicológica , Nicotina , Refuerzo en Psicología , Animales , Femenino , Masculino , Nicotina/farmacología , Nicotina/administración & dosificación , Ratas , Extinción Psicológica/efectos de los fármacos , Condicionamiento Operante/efectos de los fármacos , Caracteres Sexuales , Ratas Sprague-Dawley , Aprendizaje Discriminativo/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacosRESUMEN
Although the phenomenon of memory formation and recall associated with the use of psychotropic drugs has been extensively studied, mechanisms underlying memories for natural reward have not been clarified. Herein, we test the hypothesis that glutamatergic receptors in the dentate gyrus play a role in memories associated with sucrose. We used pellet self-administration protocol to generate memories in two-port nose-poke discrimination task using male Wistar rats. During non-rewarded probe trial, the conditioned animals readily discriminated the active port versus inactive port and showed massive increase in mRNA expression of AMPA receptor subunit genes (gria2, gria3) as well as c-Fos protein in the DG. Access to sweet pellet further enhanced c-Fos expression in the DG. However, animals pre-treated with AMPA receptor antagonist CNQX (intra-DG), on exposure to operant chamber (no pellet), showed decreased discrimination as well as c-Fos expression. We suggest that AMPA receptors in DG mediate recall and consolidation of memories associated with sucrose consumption. CNQX pre-treated animals, if presented with sweet pellet on nose poke, exhibited high discrimination index coupled with increased c-Fos expression. In these CNQX treated rats, the DI was again decreased following administration of NMDA receptor antagonist AP5. We suggest that, although AMPA receptors are blocked, the access to sweet pellet may induce surge of glutamate in the DG, which in turn may reinstate memories via activation of erstwhile silent synapses in NMDA dependant manner.
Asunto(s)
Giro Dentado , Receptores AMPA , Receptores de N-Metil-D-Aspartato , Sacarosa , Animales , Masculino , Ratas , 6-Ciano 7-nitroquinoxalina 2,3-diona/farmacología , Condicionamiento Operante/efectos de los fármacos , Condicionamiento Operante/fisiología , Giro Dentado/efectos de los fármacos , Giro Dentado/metabolismo , Aprendizaje Discriminativo/efectos de los fármacos , Aprendizaje Discriminativo/fisiología , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Antagonistas de Aminoácidos Excitadores/farmacología , Memoria/fisiología , Memoria/efectos de los fármacos , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ratas Wistar , Receptores AMPA/metabolismo , Receptores AMPA/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/metabolismo , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , ARN Mensajero/metabolismo , Autoadministración , Sacarosa/administración & dosificaciónRESUMEN
Cannabis is a pharmacologically complex plant consisting of hundreds of potentially active compounds. One class of compounds present in cannabis that has received little attention are terpenes. Traditionally thought to impart aroma and flavor to cannabis, it has become increasingly recognized that terpenes might exert therapeutic effects themselves. Several recent reports have also indicated terpenes might behave as cannabinoid type 1 (CB1) receptor agonists. This study aimed to investigate whether several terpenes present in cannabis produce discriminative stimulus effects similar to or enhance the effects of Δ 9 -tetrahydrocannabinol (THC). Subsequent experiments explored other potential cannabimimetic effects of these terpenes. Rats were trained to discriminate THC from vehicle while responding under a fixed-ratio 10 schedule of food presentation. Substitution testing was performed with the CB receptor agonist JWH-018 and the terpenes linalool, limonene, γ-terpinene and α-humulene alone. Terpenes were also studied in combination with THC. Finally, THC and terpenes were tested in the tetrad assay to screen for CB1-receptor agonist-like effects. THC and JWH-018 dose-dependently produced responding on the THC-paired lever. When administered alone, none of the terpenes produced responding predominantly on the THC-paired lever. When administered in combination with THC, none of the terpenes enhanced the potency of THC, and in the case of α-humulene, decreased the potency of THC to produce responding on the THC-paired lever. While THC produced effects in all four tetrad components, none of the terpenes produced effects in all four components. Therefore, the terpenes examined in this report do not have effects consistent with CB1 receptor agonist properties in the brain.
Asunto(s)
Cannabis , Dronabinol , Terpenos , Animales , Terpenos/farmacología , Ratas , Dronabinol/farmacología , Masculino , Cannabinoides/farmacología , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/metabolismo , Indoles/farmacología , Naftalenos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Ratas Sprague-Dawley , Relación Dosis-Respuesta a Droga , Aprendizaje Discriminativo/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacosRESUMEN
Gabapentin is used for the treatment of many conditions, including seizures, pain, and anxiety. Increasing reports of nonprescribed use suggest that gabapentin may elicit positive subjective effects. The present study was conducted to examine the subjective effects of gabapentin using rats trained to discriminate either a 30.0 mg/kg or 300.0 mg/kg dose of gabapentin versus vehicle on a two-choice drug discrimination task. Both doses of gabapentin were established as discriminative stimuli, and the 300.0 mg/kg dose was more readily established compared to the 30.0 mg/kg dose. Full substitution (> 80% gabapentin-lever responding) occurred by the training drug and by the gabapentinoid compound pregabalin. Partial substitution (> 20% gabapentin-lever responding) was shown by the opioid compounds morphine and fentanyl, and dose combinations of the opioid receptor antagonist naltrexone with the gabapentin training doses reduced the percentage of gabapentin-lever responding to below 80%. Partial substitution for both training doses of gabapentin occurred with the cannabinoid Δ9-tetrahydrocannabinol. The barbiturate compound pentobarbital and the benzodiazepine compound diazepam were only tested for substitution for the 300.0 mg/kg dose of gabapentin and these compounds produced full substitution. These findings demonstrate that gabapentin establishes a robust discriminative cue and exhibits stimulus effects closely similar to pregabalin, pentobarbital, and diazepam. Since pregabalin, pentobarbital, and diazepam carry a risk of problematic use and are classified as controlled substances, further evaluations of gabapentin's risks in this regard are warranted. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Asunto(s)
Aminas , Diazepam , Gabapentina , Pentobarbital , Pregabalina , Ratas Sprague-Dawley , Ácido gamma-Aminobutírico , Animales , Gabapentina/farmacología , Gabapentina/administración & dosificación , Pregabalina/farmacología , Pregabalina/administración & dosificación , Ratas , Masculino , Diazepam/farmacología , Diazepam/administración & dosificación , Ácido gamma-Aminobutírico/farmacología , Ácido gamma-Aminobutírico/análogos & derivados , Ácido gamma-Aminobutírico/administración & dosificación , Pentobarbital/farmacología , Pentobarbital/administración & dosificación , Aminas/farmacología , Aminas/administración & dosificación , Relación Dosis-Respuesta a Droga , Ácidos Ciclohexanocarboxílicos/farmacología , Ácidos Ciclohexanocarboxílicos/administración & dosificación , Discriminación en Psicología/efectos de los fármacos , Sustitución de Medicamentos/métodos , Aprendizaje Discriminativo/efectos de los fármacosRESUMEN
Extracting relevant information and transforming it into appropriate behavior, is a fundamental brain function, and requires the coordination between the sensory and cognitive systems, however, the underlying mechanisms of interplay between sensory and cognition systems remain largely unknown. Here, we developed a mouse model for mimicking human auditory mismatch negativity (MMN), a well-characterized translational biomarker for schizophrenia, and an index of early auditory information processing. We found that a subanesthetic dose of ketamine decreased the amplitude of MMN in adult mice. Using pharmacological and chemogenetic approaches, we identified an auditory cortex-entorhinal cortex-hippocampus neural circuit loop that is required for the generation of MMN. In addition, we found that inhibition of dCA1âMEC circuit impaired the auditory related fear discrimination. Moreover, we found that ketamine induced MMN deficiency by inhibition of long-range GABAergic projection from the CA1 region of the dorsal hippocampus to the medial entorhinal cortex. These results provided circuit insights for ketamine effects and early auditory information processing. As the entorhinal cortex is the interface between the neocortex and hippocampus, and the hippocampus is critical for the formation, consolidation, and retrieval of episodic memories and other cognition, our results provide a neural mechanism for the interplay between the sensory and cognition systems.
Asunto(s)
Corteza Auditiva/fisiología , Percepción Auditiva/fisiología , Corteza Entorrinal/fisiología , Potenciales Evocados Auditivos/fisiología , Antagonistas de Aminoácidos Excitadores/farmacología , Hipocampo/fisiología , Ketamina/farmacología , Red Nerviosa/fisiología , Animales , Corteza Auditiva/efectos de los fármacos , Percepción Auditiva/efectos de los fármacos , Región CA1 Hipocampal/efectos de los fármacos , Región CA1 Hipocampal/fisiología , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Corteza Entorrinal/efectos de los fármacos , Potenciales Evocados Auditivos/efectos de los fármacos , Miedo/fisiología , Hipocampo/efectos de los fármacos , Ratones , Red Nerviosa/efectos de los fármacosRESUMEN
BACKGROUND: Cognitive decline after oral administration of sedatives, such as benzodiazepines, is a serious side effect. Suvorexant, an orexin receptor antagonist, has a favorable tolerability and a limited side-effect profile. AIM: The purpose of this study was to estimate the cognitive decline 1 day after oral medication with lormetazepam, a benzodiazepine, and suvorexant by comparing mismatch negativity (MMN) and P300 reflecting auditory discrimination function. METHODS: Sixty healthy subjects (42 males) were randomly assigned to three groups receiving suvorexant 20 mg, lormetazepam 2 mg, or placebo in this double-blind, randomized control study. Event-related potential recordings during an auditory oddball task and a digit symbol substitution test (DSST) were performed 1 day after oral administration. RESULTS: MMN, on the day after oral administration, was significantly attenuated in the lormetazepam group compared with the other two groups, but there was no difference between the suvorexant and placebo groups. No significant difference was found in P300 amplitudes and DSST scores among the three groups. CONCLUSION: These findings suggest that suvorexant, unlike benzodiazepine, is not associated with cognitive deficits, as revealed by MMN but not P300. This study shows a neurophysiological difference in the effects of suvorexant and benzodiazepine on cognitive function.
Asunto(s)
Percepción Auditiva/efectos de los fármacos , Azepinas/farmacología , Benzodiazepinas/farmacología , Disfunción Cognitiva/inducido químicamente , Discriminación en Psicología/efectos de los fármacos , Potenciales Evocados Auditivos/efectos de los fármacos , Lorazepam/análogos & derivados , Antagonistas de los Receptores de Orexina/farmacología , Triazoles/farmacología , Adulto , Azepinas/administración & dosificación , Azepinas/efectos adversos , Benzodiazepinas/administración & dosificación , Benzodiazepinas/efectos adversos , Electroencefalografía , Potenciales Relacionados con Evento P300/efectos de los fármacos , Femenino , Humanos , Lorazepam/administración & dosificación , Lorazepam/efectos adversos , Lorazepam/farmacología , Masculino , Antagonistas de los Receptores de Orexina/administración & dosificación , Antagonistas de los Receptores de Orexina/efectos adversos , Triazoles/administración & dosificación , Triazoles/efectos adversos , Adulto JovenRESUMEN
Electrophysiological studies show that nicotine enhances neural responses to characteristic frequency stimuli. Previous behavioral studies partially corroborate these findings in young adults, showing that nicotine selectively enhances auditory processing in difficult listening conditions. The present work extended previous work to include both young and older adults and assessed the nicotine effect on sound frequency and intensity discrimination. Hypotheses were that nicotine improves auditory performance and that the degree of improvement is inversely proportional to baseline performance. Young (19-23 years old) normal-hearing nonsmokers and elderly (61-80) nonsmokers with normal hearing between 500 and 2000 Hz received nicotine gum (6 mg) or placebo gum in a single-blind, randomized crossover design. Participants performed three experiments (frequency discrimination, frequency modulation identification, and intensity discrimination) before and after treatment. The perceptual differences were analyzed between pre- and post-treatment, as well as between post-treatment nicotine and placebo conditions as a function of pre-treatment baseline performance. Compared to pre-treatment performance, nicotine significantly improved frequency discrimination. Compared to placebo, nicotine significantly improved performance for intensity discrimination, and the improvement was more pronounced in the elderly with lower baseline performance. Nicotine had no effect on frequency modulation identification. Nicotine effects are task-dependent, reflecting possible interplays of subjects, tasks and neural mechanisms.
Asunto(s)
Envejecimiento/fisiología , Percepción Auditiva/efectos de los fármacos , Nicotina/farmacología , No Fumadores , Afecto/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Estudios Cruzados , Discriminación en Psicología/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nicotina/administración & dosificación , Chicles de Nicotina , No Fumadores/psicología , Oxígeno/sangre , Percepción de la Altura Tonal/efectos de los fármacos , Desempeño Psicomotor , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/fisiología , Proyectos de Investigación , Relación Señal-Ruido , Método Simple Ciego , Adulto JovenRESUMEN
While there is a strong focus on the negative consequences of maternal immune activation (MIA) on developing brains, very little attention is directed towards potential advantages of early life challenges. In this study, we utilized a polyinosine-polycytidylic acid (poly(I:C)) MIA model to test visual pairwise discrimination (PD) and reversal learning (RL) in mice using touchscreen technology. Significant sex differences emerged in that MIA reduced the latency for males to make a correct choice in the PD task while females reached criterion sooner, made fewer errors, and utilized fewer correction trials in RL compared to saline controls. These surprising improvements were accompanied by the sex-specific upregulation of several genes critical to cognitive functioning, indicative of compensatory plasticity in response to MIA. In contrast, when exposed to a 'two-hit' stress model (MIA + loss of the social component of environmental enrichment [EE]), mice did not display anhedonia but required an increased number of PD and RL correction trials. These animals also had significant reductions of CamK2a mRNA in the prefrontal cortex. Appropriate functioning of synaptic plasticity, via mediators such as this protein kinase and others, are critical for behavioral flexibility. Although EE has been implicated in, delaying the appearance of symptoms associated with certain brain disorders, these findings are in line with evidence that it also makes individuals more vulnerable to its loss. Overall, with the right 'dose', early life stress exposure can confer at least some functional advantages, which are lost when the number or magnitude of these exposures become too great.
Asunto(s)
Discriminación en Psicología/efectos de los fármacos , Poli I-C/farmacología , Aprendizaje Inverso/efectos de los fármacos , Factores Sexuales , Percepción Visual/inmunología , Animales , Atención/efectos de los fármacos , Conducta Animal/fisiología , Cognición/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Ratones , Embarazo , Efectos Tardíos de la Exposición Prenatal/inmunología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Percepción Visual/efectos de los fármacos , Percepción Visual/fisiologíaRESUMEN
RATIONALE: As a treatment for cognitive dysfunction in schizophrenia, oxytocin nasal sprays potentially improve social cognition, facial expression recognition, and sense of smell. Mismatch negativity (MMN) is an event-related potential (ERP) reflecting auditory discrimination while MMN deficits reflect cognitive function decline in schizophrenia. OBJECTIVES: To determine whether oxytocin nasal spray affects auditory MMN METHODS: We measured ERPs in healthy subjects during an auditory oddball task, both before and after oxytocin nasal spray administration. Forty healthy subjects were randomly assigned to either the oxytocin or placebo group. ERPs were recorded during the oddball task for all subjects before and after a 24 international unit (IU) intranasal administration, and MMN was compared between the two groups. RESULTS: Participants who received oxytocin had significantly shorter MMN latencies than those who received a placebo. Oxytocin had no significant effect on the Change in MMN amplitude. CONCLUSIONS: The shortened MMN latencies that were observed after oxytocin nasal spray administration suggest that oxytocin may promote the comparison-decision stage.
Asunto(s)
Estimulación Acústica/métodos , Percepción Auditiva/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacos , Potenciales Evocados Auditivos/efectos de los fármacos , Rociadores Nasales , Oxitocina/administración & dosificación , Adulto , Percepción Auditiva/fisiología , Discriminación en Psicología/fisiología , Método Doble Ciego , Electroencefalografía/métodos , Potenciales Evocados Auditivos/fisiología , Femenino , Humanos , Masculino , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/fisiopatología , Adulto JovenRESUMEN
The endogenous opioid system is strongly involved in the modulation of pain. However, the potential role of this system in perceiving painful facial expressions from others has not been sufficiently explored as of yet. To elucidate the contribution of the opioid system to the perception of painful facial expressions, we conducted a double-blind, within-subjects pharmacological functional magnetic resonance imaging (fMRI) study, in which 42 participants engaged in an emotion discrimination task (pain vs. disgust expressions) in two experimental sessions, receiving either the opioid receptor antagonist naltrexone or an inert substance (placebo). On the behavioral level, participants less frequently judged an expression as pain under naltrexone as compared to placebo. On the neural level, parametric modulation of activation in the (putative) right fusiform face area (FFA), which was correlated with increased pain intensity, was higher under naltrexone than placebo. Regression analyses revealed that brain activity in the right FFA significantly predicted behavioral performance in disambiguating pain from disgust, both under naltrexone and placebo. These findings suggest that reducing opioid system activity decreased participants' sensitivity for facial expressions of pain, and that this was linked to possibly compensatory engagement of processes related to visual perception, rather than to higher level affective processes, and pain regulation.
Asunto(s)
Discriminación en Psicología/fisiología , Expresión Facial , Reconocimiento Facial/fisiología , Naltrexona/farmacología , Antagonistas de Narcóticos/farmacología , Dolor , Percepción Social , Lóbulo Temporal/fisiología , Adulto , Discriminación en Psicología/efectos de los fármacos , Asco , Método Doble Ciego , Reconocimiento Facial/efectos de los fármacos , Femenino , Neuroimagen Funcional , Humanos , Imagen por Resonancia Magnética , Masculino , Lóbulo Temporal/diagnóstico por imagen , Lóbulo Temporal/efectos de los fármacos , Adulto JovenRESUMEN
BACKGROUND: A previously acquired fear response often spreads to perceptually or conceptually close stimuli or contexts. This process, known as fear generalization, facilitates the avoidance of danger, and dysregulations in this process play an important role in anxiety disorders. Oxytocin (OT) has been shown to modulate fear learning, yet effects on fear generalization remain unknown. METHODS: We employed a randomized, placebo-controlled, double-blind, between-subject design during which healthy male participants received either intranasal OT or placebo (PLC) following fear acquisition and before fear generalization with concomitant acquisition of skin conductance responses (SCRs). Twenty-four to 72 h before the fear learning and immediately after the fear generalization task, participants additionally complete a discrimination threshold task. RESULTS: Relative to PLC, OT significantly reduced perceived risk and SCRs towards the CS+ and GS1 (the generalization stimulus that is most similar to CS+) during fear generalization, whereas the discrimination threshold was not affected. CONCLUSIONS: Together, the results suggest that OT can attenuate fear generalization in the absence of effects on discrimination threshold. This study provides the first evidence for effects of OT on fear generalization in humans and suggests that OT may have therapeutic potential in anxiety disorders characterized by dysregulated fear generalization.
Asunto(s)
Trastornos de Ansiedad/tratamiento farmacológico , Discriminación en Psicología/efectos de los fármacos , Miedo/efectos de los fármacos , Generalización Psicológica/efectos de los fármacos , Oxitocina/farmacología , Administración Intranasal , Adulto , Condicionamiento Clásico/efectos de los fármacos , Método Doble Ciego , Reconocimiento Facial/efectos de los fármacos , Miedo/psicología , Femenino , Humanos , Aprendizaje/efectos de los fármacos , Masculino , Oxitocina/administración & dosificación , Adulto JovenRESUMEN
OBJECTIVE: The purpose of this study was to evaluate the effect of astaxanthin (AST) on cognition function, inflammatory response and oxidative stress in vascular dementia (VD) mice. METHOD: VD mice model was established by left unilateral common carotid arteries occlusion (LUCCAO). Following LUCCAO, AST was intragastrically administered for 30 days. Object recognition test and morris water maze test were used to evaluate cognitive function. Hematoxylin and eosin staining was performed to observe the hippocampal neuron structure. Enzyme-linked immunosorbent assay kit and bicinchoninic acid kit were respectively adopted to measure IL-1ß and IL-4 protein expression and superoxide dismutase (SOD) activity and malondialdehyde (MDA) content in hippocampus and prefrontal cortex. RESULTS: AST improved the discrimination ability of VD mice. The escape latency and path length of VD mice treated with AST were dramatically reduced. Besides, AST 200 mg/kg enhanced crossing platform time and the number of times crossing the platform quadrant, and alleviated the morphological impairment in VD mice. Moreover, we found that AST inhibited IL-1ß expression and MDA content, whereas promoted IL-4 expression and SOD activity in a dose-dependent manner. CONCLUSION: AST could improve cognitive impairment and hippocampal neurons in VD mice, which may be related to suppression of inflammatory response and oxidative stress.
Asunto(s)
Trastornos del Conocimiento/prevención & control , Trastornos del Conocimiento/psicología , Demencia Vascular/tratamiento farmacológico , Demencia Vascular/psicología , Fármacos Neuroprotectores/uso terapéutico , Animales , Demencia Vascular/patología , Discriminación en Psicología/efectos de los fármacos , Hipocampo/patología , Interleucina-1beta/biosíntesis , Interleucina-1beta/genética , Interleucina-4/biosíntesis , Interleucina-4/genética , Masculino , Malondialdehído/metabolismo , Ratones , Ratones Endogámicos ICR , Prueba del Laberinto Acuático de Morris , Corteza Prefrontal/patología , Desempeño Psicomotor/efectos de los fármacos , Reconocimiento en Psicología , Superóxido Dismutasa/metabolismo , Xantófilas/uso terapéuticoRESUMEN
INTRODUCTION: The assessment of the abuse potential of CNS-active drugs is a regulatory requirement. Drug discrimination is one of the nonclinical tests that contribute to this assessment by providing information on a drug's potential to induce a discriminative stimulus comparable to that of a known drug of abuse. AIM: The objective was to validate drug discrimination in the rat for the purpose of supporting regulatory submissions for novel drugs with potential cannabinoid-like activity. METHODS: Ten female Lister hooded rats were trained to discriminate no-drug from Δ9-THC (1.5 mg/kg, IP) under a FR10 schedule of reinforcement. Once trained, a Δ9-THC dose-response curve was obtained using doses of 0.25, 0.75, 1.5, and 3 mg/kg, IP. This was followed by evaluation of amphetamine (0.3 mg/kg, SC); morphine (3 mg/kg, IP); midazolam (2.5 mg/kg, PO); and the synthetic cannabinoids WIN55,212-2 (0.75 to 2 mg/kg, IP), CP-47,497 (0.5 to 2 mg/kg, IP), and JWH-018 (1 mg/kg, IP) for their discriminative stimulus similarity to Δ9-THC. RESULTS: Pharmacological specificity was demonstrated by achieving the anticipated dose-response curve for Δ9-THC, and a vehicle-like response for the non-cannabinoid drugs. Although full generalisation was obtained for JWH-018, in contrast to published literature, WIN55,212-2 and CP-47,497 failed to generalise to Δ9-THC. DISCUSSION: Based on the literature review performed in light of the results obtained, contrasting and unpredictable behavioural responses produced by cannabinoids in animals and humans raises the question of the reliability and relevance of including drug discrimination and self-administration studies within an abuse potential assessment for novel cannabinoid-like drugs.
Asunto(s)
Discriminación en Psicología/efectos de los fármacos , Dronabinol/efectos adversos , Trastornos Relacionados con Sustancias/prevención & control , Anfetamina/administración & dosificación , Anfetamina/efectos adversos , Animales , Benzoxazinas/administración & dosificación , Benzoxazinas/efectos adversos , Ciclohexanoles/administración & dosificación , Ciclohexanoles/efectos adversos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Dronabinol/administración & dosificación , Evaluación Preclínica de Medicamentos/métodos , Femenino , Humanos , Indoles/administración & dosificación , Indoles/efectos adversos , Inyecciones Intraperitoneales , Midazolam/administración & dosificación , Midazolam/efectos adversos , Morfina/administración & dosificación , Morfina/efectos adversos , Morfolinas/administración & dosificación , Morfolinas/efectos adversos , Naftalenos/administración & dosificación , Naftalenos/efectos adversos , Ratas , Refuerzo en Psicología , Reproducibilidad de los Resultados , Automedicación , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/etiologíaRESUMEN
Lesions of the dorsomedial striatum elicit deficits in cognitive flexibility that are an early feature of Parkinson's disease (PD), and presumably reflect alterations in frontostriatal processing. The current study aimed to examine deficits in cognitive flexibility in rats with bilateral 6-hydroxydopamine lesions in the dorsomedial striatum. While deficits in cognitive flexibility have previously been examined in rodent PD models using the cross-maze, T-maze, and a food-digging task, the current study is the first to examine such deficits using a 3-choice serial reaction time task (3-CSRT) with reversal learning (3-CSRT-R). Although the rate of acquisition in 3-CSRT was slower in lesioned compared to control rats, lesioned animals were able to acquire a level of accuracy comparable to that of control animals following 4 weeks of training. In contrast, substantial and persistent deficits were apparent during the reversal learning phase. Our results demonstrate that deficits in cognitive flexibility can be robustly unmasked by reversal learning in the 3-CSRT-R paradigm, which can be a useful test for evaluating effects of dorsomedial striatal deafferentation and interventions.
Asunto(s)
Conducta de Elección/fisiología , Disfunción Cognitiva/patología , Cuerpo Estriado/patología , Oxidopamina/toxicidad , Tiempo de Reacción/fisiología , Aprendizaje Inverso/fisiología , Animales , Conducta de Elección/efectos de los fármacos , Cognición/efectos de los fármacos , Cognición/fisiología , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/psicología , Cuerpo Estriado/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacos , Discriminación en Psicología/fisiología , Masculino , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos , Aprendizaje Inverso/efectos de los fármacosRESUMEN
Although (S)-ketamine was approved for use in treatment-resistant depression in 2019, new preclinical findings suggest that (R)-ketamine might produce better efficacy and tolerability relative to (S)-ketamine. Here we evaluated the effects of (R)-, (S)-, and (R,S)-ketamine on executive functions as measured in the attentional set shifting task (ASST) and on their discriminative stimulus effects in rats. Earlier data demonstrated that cognitive flexibility is compromised by (R,S)-ketamine, but the effects of enantiomers in rats are unknown. Separate cohorts of rats were tested in ASST and trained to discriminate either (R,S)-ketamine, (S)-ketamine, or (R)-ketamine (all at 10 mg/kg) from saline; in order to maintain the discrimination, a higher (R)-ketamine dose (17.5 mg/kg) was subsequently instituted. In ASST, all three forms increased the trials to criterion measure at reversal learning and extra-dimensional set-shifting phases. However, in contrast to (R)- and (S)-ketamine, (R,S)-ketamine prolonged the mean time to complete a single trial during early stages, suggesting increased reaction time, and/or unspecific side-effects related to motor or motivational impairments. In the drug discriminations, all rats acquired their respective discriminations between drug and saline. In (R,S)-ketamine-trained rats, (R)-ketamine and (S)-ketamine only partially substituted for the training dose of (R,S)-ketamine. Further, (R)-ketamine did not fully substitute in rats trained to (S)-ketamine. The data suggest more serious cognitive deficits produced by (R,S)-ketamine than its enantiomers. Furthermore, (R,S)-ketamine and its isomers share overlapping but not isomorphic discriminative stimulus effects predicting distinct subjective responses to (R)- vs. (S)-ketamine in humans.
Asunto(s)
Cognición/efectos de los fármacos , Aprendizaje Discriminativo/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/química , Antagonistas de Aminoácidos Excitadores/farmacología , Ketamina/química , Ketamina/farmacología , Animales , Relación Dosis-Respuesta a Droga , Función Ejecutiva/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , EstereoisomerismoRESUMEN
BACKGROUND: Chemokine C-C motif ligand 2 (CCL2) is one of the most widely recognised proinflammatory chemokines in cognitive disorders. Currently, CCL2-targeting drugs are extremely limited. Thus, this study aimed to explore the neuroprotection afforded by naringin in CCL2-induced cognitive impairment in rats. METHODS: Before the CCL2 intra-hippocampal injection, rats were treated with naringin for 3 consecutive days via intraperitoneal injection. Two days post-surgery, the Morris water maze (MWM) and novel object recognition (NORT) tests were performed to detect spatial learning and memory and object cognition, respectively. Nissl staining and dUTP nick-end labelling (TUNEL) staining were performed to assess histopathological changes in the hippocampus. Commercial kits were used to measure the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the content of malondialdehyde (MDA). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine the relative mRNA expression of interleukin 1ß, (IL-1ß), interleukin 6 (IL-6), glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT-1), phosphate-activated glutaminase (PAG), cysteine aspartic acid-specific protease 8 (caspase-8), cysteine aspartic acid-specific protease 3 (caspase-3), cell lymphoma/leukaemia-2 (Bcl-2), and Bcl-2 associated X protein (Bax). RESULTS: In the MWM, the average escape latency and average swimming distance were significantly reduced and the crossing times were increased in the naringin-treated groups, compared with the CCL2 group. The NORT results revealed that, compared with the CCL2 rats, the discrimination index in the naringin-treated rats increased significantly. Nissl and TUNEL staining revealed that naringin protected the structure and survival of the neurons in the CA1 zone of the hippocampus. In the naringin-treated groups, the SOD and GSH-Px activities were increased, whereas the MDA levels were decreased. Furthermore, in the naringin-treated groups, the relative mRNA expression of IL-1ß and IL-6 was significantly decreased; GLAST and GLT-1 mRNA expression levels were increased, whereas PAG was decreased. In the naringin-treated groups, the relative mRNA expression levels of caspase-8, caspase-3, and Bax were decreased, whereas that of Bcl-2 was increased. CONCLUSION: Collectively, these data indicated that naringin alleviated the CCL2-induced cognitive impairment. The underlying mechanisms could be associated with the inhibition of neuroinflammation, oxidative stress, apoptosis, and the regulation of glutamate metabolism.